Elaine Husni, MD, MPH: Biosimilars and Cost Savings for Patients
December 31st 2019Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic, discusses whether biosimilars are generating cost savings for patients with inflammatory diseases.
Jeffrey Patton, MD: Adopting Biosimilar Trastuzumab, Bevacizumab, and Rituximab in the Clinic
November 25th 2019Jeffrey Patton, MD, chief executive officer of Tennessee Oncology and president of physician services for OneOncology, discusses adoption of biosimilar trastuzumab, bevacizumab, and rituximab.
Cate Lockhart, PharmD, PhD: Challenges With Large-Scale Comparative Effectiveness Research
November 22nd 2019Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), discusses the challenges inherent in conducting large-scale comparative effectiveness research on biologics and biosimilars.
Elaine Husni, MD, MPH: Rheumatologists' Comfort With Biosimilars
November 13th 2019Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic, discusses how comfortable rheumatologists are with using biosimilars.